Silo Pharma Subsidiary QwikAgents Joins AMD AI Developer Program

Silo Pharma's subsidiary QwikAgents has been accepted into AMD's AI Developer Program, gaining access to cloud credits and tools to accelerate its AI agent platform development.

Dallas Metrowire Staff
Technology
Silo Pharma Subsidiary QwikAgents Joins AMD AI Developer Program

Silo Pharma (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices’ AMD AI Developer Program. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community. This acceptance is expected to accelerate the development, testing, optimization, and deployment of QwikAgents' AI agent platform across consumer and enterprise applications.

QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding, and workflow automation. According to Silo Pharma, participation in the AMD AI Developer Program is expected to support platform performance, agent reliability, and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses, and enterprise customers.

This partnership marks a strategic milestone for Silo Pharma as it diversifies into AI technology through its subsidiary. The AMD AI Developer Program is designed to help developers optimize their software for AMD hardware, which could enhance the efficiency and speed of QwikAgents' AI agents. By leveraging AMD's development resources, QwikAgents aims to improve its platform's performance and reliability, potentially gaining a competitive edge in the rapidly growing AI agent market.

The implications of this announcement extend beyond Silo Pharma's immediate business. The collaboration highlights a trend of biopharmaceutical companies exploring AI to streamline operations and create new revenue streams. For Silo Pharma, which primarily focuses on developing treatments for stress-induced psychiatric disorders, chronic pain, and CNS diseases, the move into AI via QwikAgents represents a strategic pivot that could provide additional financial stability and growth opportunities.

AMD's AI Developer Program is part of the company's broader initiative to foster an ecosystem around its AI hardware and software. By accepting QwikAgents into the program, AMD gains a partner that can showcase the capabilities of its technology in real-world applications. For developers and enterprises, this partnership signals increased accessibility to advanced AI tools and resources, potentially lowering barriers to entry for AI adoption.

Blockchain Registration

QR Code for Blockchain Registration